Article Versions Notes

Højer Wang L, Wehland M, Wise PM, Infanger M, Grimm D, Kreissl MC. Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect. International Journal of Molecular Sciences. 2023; 24(3):2312. https://doi.org/10.3390/ijms24032312

Højer Wang, Linnea, Markus Wehland, Petra M. Wise, Manfred Infanger, Daniela Grimm, and Michael C. Kreissl. 2023. "Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect" International Journal of Molecular Sciences 24, no. 3: 2312. https://doi.org/10.3390/ijms24032312

Højer Wang, L., Wehland, M., Wise, P. M., Infanger, M., Grimm, D., & Kreissl, M. C. (2023). Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect. International Journal of Molecular Sciences, 24(3), 2312. https://doi.org/10.3390/ijms24032312